Contents Haematological Malignancies
Treatment Options for Myelodysplastic Syndromes Hillary Prescott,1
Elias Jabbour,2 Jeffrey Bryan1 200 and Hagop Kantarjian3
1. Clinical Pharmacy Specialist; 2. Assistant Professor; 3. Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Novel Therapy of Relapsed and Refractory Classical Hodgkin’s Lymphoma Enrico Derenzini,1
Daniela Buglio1 and Anas Younes2
1. Postdoctoral Fellow; 2. Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
Transplantation
Allogeneic Haematopoietic Stem Cell Donation – Current Status with Regard to Safety Alberto Bosi1
and Benedetta Bartolozzi1
1. Full Professor of Haematology; 2. Fellow, Department of Haematology, Bone Marrow Transplantation Unit, University of Florence
Thalassaemia
Thalassaemia as a Hypercoagulable State Maria D Cappellini,1
Khaled M Musallam2 214 and Ali T Taher3
1. Professor of Medicine, Department of Internal Medicine, Fondazione IRCCS “Ca’ Granda” Ospedale Policlinico, University of Milan; 2. Clinical Research Fellow; 3. Professor of Medicine, Department of Internal Medicine, Hematology–Oncology Division, American University of Beirut Medical Center
211 203
Erratum First Published: European Oncology & Haematology, 2011;7(2):109–15
The Evolving Role of Chemotherapy and Predictive Markers in Early-stage Non-small-cell Lung Cancer
Eric W Humke1 and Heather Wakelee2
1. Instructor of Medicine; 2. Assistant Professor of Medicine, Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine
In the original article, Figures 6 and 7 contained minor errors. The corrected figures are published below. European Oncology & Haematology regrets these errors and would like to extend its apologies to the authors.
Figure 6: TASTE Trial Overview
Eligible: n=108
Resected II–IIIA non-N2
Histology other than squamous cell
Cisplatin/pemetrexed x 4 cycles
Stratified:
• ERCC1 levels • EGFR status • Chemotherapy regimen
Randomised
EGFR mutant EGFR wild-type
High ERCC1 Low ERCC1
Erlotinib 150 mg PO every day x 1 year
Observation
Cisplatin/ pemetrexed x 4 cycles
Primary end-point: feasibility followed by disease-free survival. EGFR = epidermal growth factor receptor; PO = orally; TASTE = Tailored post-surgical therapy in early stage NSCLC.
158
No prior chemotherapy No prior XRT
Figure 7: SCAT Trial Overview
Eligible: n=432
Resected II–IIIA
Cisplatin/docetaxel x 4 cycles
Stratified:
• BRCA mRNA • Adjuvant chemotherapy
High BRCA1 Medium BRCA1 Low BRCA1
Randomised
Docetaxel 4 x cycles
Cisplatin/docetaxel x 4 cycles
Cisplatin/ gemcitabine x 4 cycles
Primary end-point: overall survival. BRCA1 = Breast cancer 1; mRNA = messenger RNA; SCAT = Spanish customised adjuvant trial; XRT = radiotherapy.
EUROPEAN ONCOLOGY & HAEMATOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68